Barely one week after Neimeth international pharmaceutical, a player in the Nigerian healthcare space, declared its nine months unaudited financial statements, rebounding to profit after a year-on-year loss, investors are gradually increasing their appetite for the ‘s stocks. The firm’s share p
```
Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```

Join BusinessDay whatsapp Channel, to stay up to date

Open In Whatsapp